Table 3

Mean disease activity at baseline and after 6 months of follow-up for patients treated with infliximab or etanercept

Disease activity, mean (SD)
InfliximabEtanercept
INFCT-P13ETNSB4
VAS patient, pain (mm)
 Baseline62 (23)59 (24)59 (24)59 (22)
 6 months32 (26)33 (28)30 (27)28 (25)
VAS patient, global (mm)
 Baseline59 (24)64 (24)57 (22)59 (23)
 6 months33 (26)37 (30)30 (27)30 (24)
ASDAS
 Baseline3.37 (1.02)3.35 (0.97)3.05 (0.90)2.98 (0.94)
 6 months1.95 (1.15)2.03 (1.18)1.67 (1.01)1.65 (0.90)
BASDAI
 Baseline5.97 (2.00)5.61 (2.03)5.36 (2.01)5.36 (1.93)
 6 months3.18 (2.32)3.37 (2.61)2.95 (2.50)2.72 (2.09)
BASFI
 Baseline4.38 (2.51)4.79 (2.38)4.06 (2.36)4.09 (2.48)
 6 months2.37 (2.50)3.01 (2.67)2.10 (2.22)1.74 (1.88)
CRP
 Baseline15 (21)13 (22)11 (18)10 (15)
 6 months6 (11)5 (11)4 (5)3 (4)
  • Numbers are means (SD) for patients with available data at the specific time point. The proportion of patients contributing data is shown in online supplementary table S1.

  • ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C reactive protein;CT-P13, infliximab biosimilar; ETN, etanercept originator; INF, infliximab originator; SB4, etanercept biosimilar; VAS, visual analogue scale.